- Home
- HURN vs PTGX Comparison
HURN vs PTGX Comparison
Compare HURN & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HURN | PTGX |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 5.4B |
| IPO Year | 2004 | 2016 |
Fundamental Metrics
Financial Performance| Metric | HURN | PTGX |
|---|---|---|
| Price | $179.75 | $94.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $190.25 | $88.33 |
| AVG Volume (30 Days) | 134.5K | ★ 953.6K |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.32 | N/A |
| EPS | ★ 5.98 | 0.72 |
| Revenue | ★ $1,618,977,000.00 | $209,217,000.00 |
| Revenue This Year | $14.19 | N/A |
| Revenue Next Year | $9.49 | $296.47 |
| P/E Ratio | ★ $30.01 | $132.39 |
| Revenue Growth | ★ 12.67 | N/A |
| 52 Week Low | $118.25 | $33.70 |
| 52 Week High | $180.29 | $95.39 |
Technical Indicators
Market Signals| Indicator | HURN | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 76.92 | 70.99 |
| Support Level | $168.79 | $88.30 |
| Resistance Level | $166.87 | $92.80 |
| Average True Range (ATR) | 4.66 | 2.82 |
| MACD | 1.02 | 0.19 |
| Stochastic Oscillator | 97.67 | 94.19 |
Price Performance
Historical ComparisonAbout HURN Huron Consulting Group Inc.
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.